Research programme: precision oral anticoagulants - Verseon
Alternative Names: PROACs; Thrombin inhibitors - Verseon; VE-DTIsLatest Information Update: 28 Aug 2019
Price :
$50 *
At a glance
- Originator Verseon
- Class Anticoagulants
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute coronary syndromes; Stroke; Venous thrombosis
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for preclinical development in Acute coronary syndromes in USA (PO)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Stroke(Prevention) in USA (PO)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Venous-thrombosis in USA (PO)